(Q37786357)

23 August 2017

title

A guide to interpreting economic studies in infectious diseases (English)

1 reference

23 August 2017

1 reference

R. R. Roberts

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20825433

9 July 2024

E. K. Mensah

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20825433

9 July 2024

R. A. Weinstein

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20825433

9 July 2024

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=20825433

9 July 2024

publication date

1 December 2010

1 reference

full work available at URL

23 August 2017

http://www.clinicalmicrobiologyandinfection.com/article/S1198743X14605723/pdf

file format

Portable Document Format

online access status

open access

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20825433

https://api.elsevier.com/content/article/PII:S1198743X14605723?httpAccept=text/xml

9 July 2024

1 reference

https://api.crossref.org/works/10.1111/J.1469-0691.2010.03366.X

https://api.elsevier.com/content/article/PII:S1198743X14605723?httpAccept=text/plain

9 July 2024

1 reference

https://api.crossref.org/works/10.1111/J.1469-0691.2010.03366.X

Clinical Microbiology and Infection

9 July 2024

published in

1 reference

23 August 2017

volume

16

1 reference

23 August 2017

issue

12

1 reference

23 August 2017

page(s)

1713-1720

1 reference

Expanded screening for HIV in the United States--an analysis of cost-effectiveness.

23 August 2017

cites work

3

1 reference

https://api.crossref.org/works/10.1111/J.1469-0691.2010.03366.X

Estimating health care-associated infections and deaths in U.S. hospitals, 2002

9 July 2024

4

1 reference

https://api.crossref.org/works/10.1111/J.1469-0691.2010.03366.X

Measuring the economic costs of antimicrobial resistance in hospital settings: summary of the Centers for Disease Control and Prevention-Emory Workshop

9 July 2024

5

1 reference

https://api.crossref.org/works/10.1111/J.1469-0691.2010.03366.X

Strategies to Prevent and Control the Emergence and Spread of Antimicrobial-Resistant Microorganisms in Hospitals. A challenge to hospital leadership

9 July 2024

6

1 reference

https://api.crossref.org/works/10.1111/J.1469-0691.2010.03366.X

Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America guidelines for developing an institutional program to enhance antimicrobial stewardship

9 July 2024

7

1 reference

https://api.crossref.org/works/10.1111/J.1469-0691.2010.03366.X

Hand hygiene noncompliance and the cost of hospital-acquired methicillin-resistant Staphylococcus aureus infection

9 July 2024

8

1 reference

https://api.crossref.org/works/10.1111/J.1469-0691.2010.03366.X

Universal surveillance for methicillin-resistant Staphylococcus aureus in 3 affiliated hospitals.

9 July 2024

10

1 reference

https://api.crossref.org/works/10.1111/J.1469-0691.2010.03366.X

The societal cost of tuberculosis: Tarrant County, Texas, 2002.

9 July 2024

11

1 reference

https://api.crossref.org/works/10.1111/J.1469-0691.2010.03366.X

Distribution of variable vs fixed costs of hospital care

9 July 2024

13

1 reference

https://api.crossref.org/works/10.1111/J.1469-0691.2010.03366.X

9 July 2024

Hospital cost functions

14

1 reference

https://api.crossref.org/works/10.1111/J.1469-0691.2010.03366.X

How to think about future health care spending

9 July 2024

15

1 reference

https://api.crossref.org/works/10.1111/J.1469-0691.2010.03366.X

Estimating costs in the economic evaluation of medical technologies

9 July 2024

17

1 reference

https://api.crossref.org/works/10.1111/J.1469-0691.2010.03366.X

The costs of visits to emergency departments

9 July 2024

19

1 reference

https://api.crossref.org/works/10.1111/J.1469-0691.2010.03366.X

The cost of care for patients with HIV from the provider economic perspective

9 July 2024

20

1 reference

https://api.crossref.org/works/10.1111/J.1469-0691.2010.03366.X

Hospital and Societal Costs of Antimicrobial‐Resistant Infections in a Chicago Teaching Hospital: Implications for Antibiotic Stewardship

9 July 2024

21

1 reference

https://api.crossref.org/works/10.1111/J.1469-0691.2010.03366.X

The use of economic modeling to determine the hospital costs associated with nosocomial infections

9 July 2024

22

1 reference

https://api.crossref.org/works/10.1111/J.1469-0691.2010.03366.X

Costs of an emergency department-based accelerated diagnostic protocol vs hospitalization in patients with chest pain: a randomized controlled trial

9 July 2024

23

1 reference

https://api.crossref.org/works/10.1111/J.1469-0691.2010.03366.X

Rates of disease progression by baseline CD4 cell count and viral load after initiating triple-drug therapy

9 July 2024

25

1 reference

https://api.crossref.org/works/10.1111/J.1469-0691.2010.03366.X

Are methods for estimating QALYs in cost-effectiveness analyses improving?

9 July 2024

26

1 reference

https://api.crossref.org/works/10.1111/J.1469-0691.2010.03366.X

Valuing reduced antibiotic use for pediatric acute otitis media

9 July 2024

28

1 reference

https://api.crossref.org/works/10.1111/J.1469-0691.2010.03366.X

Utility measurement in healthcare: the things I never got to.

9 July 2024

29

1 reference

https://api.crossref.org/works/10.1111/J.1469-0691.2010.03366.X

Use of quality-adjusted life years for the estimation of effectiveness of health care: A systematic literature review

9 July 2024

30

1 reference

https://api.crossref.org/works/10.1111/J.1469-0691.2010.03366.X

9 July 2024

QALYs: the basics.

32

1 reference

https://api.crossref.org/works/10.1111/J.1469-0691.2010.03366.X

The cost effectiveness of combination antiretroviral therapy for HIV disease.

9 July 2024

33

1 reference

https://api.crossref.org/works/10.1111/J.1469-0691.2010.03366.X

Early versus standard antiretroviral therapy for HIV-infected adults in Haiti

9 July 2024

34

1 reference

https://api.crossref.org/works/10.1111/J.1469-0691.2010.03366.X

The survival benefits of AIDS treatment in the United States

9 July 2024

35

1 reference

https://api.crossref.org/works/10.1111/J.1469-0691.2010.03366.X

Antiretroviral treatment of adult HIV infection: 2010 recommendations of the International AIDS Society-USA panel

9 July 2024

36

1 reference

https://api.crossref.org/works/10.1111/J.1469-0691.2010.03366.X

Routine opt-out rapid HIV screening and detection of HIV infection in emergency department patients

9 July 2024

37

1 reference

https://api.crossref.org/works/10.1111/J.1469-0691.2010.03366.X

Intangibility in intertemporal choice

9 July 2024

38

1 reference

https://api.crossref.org/works/10.1111/J.1469-0691.2010.03366.X

Toward consistency in cost-utility analyses: using national measures to create condition-specific values

9 July 2024

39

1 reference

https://api.crossref.org/works/10.1111/J.1469-0691.2010.03366.X

Are QALYs based on time trade-off comparable?--A systematic review of TTO methodologies

9 July 2024

40

1 reference

https://api.crossref.org/works/10.1111/J.1469-0691.2010.03366.X

Developing methods that really do value the 'Q' in the QALY.

9 July 2024

41

1 reference

https://api.crossref.org/works/10.1111/J.1469-0691.2010.03366.X

Editorial: On the benefits of modeling using QALYs for societal resource allocation: the model is the message

9 July 2024

42

1 reference

https://api.crossref.org/works/10.1111/J.1469-0691.2010.03366.X

Are subjective well-being measures any better than decision utility measures?

9 July 2024

43

1 reference

https://api.crossref.org/works/10.1111/J.1469-0691.2010.03366.X

Prospect Theory: An Analysis of Decision under Risk

9 July 2024

44

1 reference

https://api.crossref.org/works/10.1111/J.1469-0691.2010.03366.X

Economic Notes: opportunity cost

9 July 2024

45

1 reference

https://api.crossref.org/works/10.1111/J.1469-0691.2010.03366.X

Cost effectiveness analysis in health care: contraindications

9 July 2024

46

1 reference

https://api.crossref.org/works/10.1111/J.1469-0691.2010.03366.X

Raising standards while watching the bottom line: making a business case for infection control

9 July 2024

47

1 reference

https://api.crossref.org/works/10.1111/J.1469-0691.2010.03366.X

The logged dependent variable, heteroscedasticity, and the retransformation problem.

9 July 2024

49

1 reference

https://api.crossref.org/works/10.1111/J.1469-0691.2010.03366.X

Estimating log models: to transform or not to transform?

9 July 2024

50

1 reference

https://api.crossref.org/works/10.1111/J.1469-0691.2010.03366.X

Econometric modeling of health care costs and expenditures: a survey of analytical issues and related policy considerations.

9 July 2024

51

1 reference

https://api.crossref.org/works/10.1111/J.1469-0691.2010.03366.X

Analysis of statistical outliers with application to whole effluent toxicity testing.

9 July 2024

52

1 reference

https://api.crossref.org/works/10.1111/J.1469-0691.2010.03366.X

The impact of time-dependent bias in proportional hazards modelling

9 July 2024

55

1 reference

https://api.crossref.org/works/10.1111/J.1469-0691.2010.03366.X

9 July 2024

Identifiers

1 reference

23 August 2017

1 reference